Effects of Atomoxetine on Cognitive Function in Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00420498|
Recruitment Status : Completed
First Posted : January 11, 2007
Last Update Posted : December 12, 2007
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Cognition Smoking||Drug: Atomoxetine (Strattera™)||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effects of Atomoxetine on Cognitive Function in Schizophrenia|
|Study Start Date :||August 2005|
|Actual Study Completion Date :||September 2007|
- To examine the effects of atomoxetine (Strattera™) on prefrontal cognitive functioning in persons with schizophrenia.
- To examine the effects of atomoxetine on positive and negative symptoms and on cigarette smoking consumption in persons with schizophrenia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00420498
|United States, Connecticut|
|Connecticut Mental Health Center, SAC-115|
|New Haven, Connecticut, United States, 06519|
|Principal Investigator:||Kristi A Sacco, Psy.D.||Yale School of Medicine|